Geftinat (Gefitinib) – 250 Mg

✅ Key Benefits

• Targeted mechanism for EGFR-mutant NSCLC

• Oral once-daily dosing ensures convenience and adherence

• Supports improved progression-free survival in clinical studies

• Generally well-tolerated, with mild to moderate side-effect profile

• Suitable for first-line or subsequent therapy, depending on mutation and guidelines

🎯 How to Use

• Take one 250 mg tablet daily, on an empty stomach (1 hour before or 2 hours after meals)

• Swallow tablets whole with a glass of water

• Continue until disease progression or unacceptable toxicity

• Monitor liver function tests and clinical response regularly

• Follow oncologist guidance on dose management in adverse events

⚠️ Precautions

• Prescription-only; must be prescribed by an oncology specialist

• Liver enzyme monitoring is essential

• Toxicity risks include interstitial lung disease (rare) —discontinue and evaluate if dyspnea or new pulmonary symptoms occur

• Use with caution in patients with pre-existing lung conditions

• Avoid pregnancy; use effective contraception during and after treatment

• Drug interactions possible—review concomitant medications

🤕 Possible Side Effects

• Common: Diarrhea, skin rash, acne, dry skin, nausea

• Laboratory: Elevated AST/ALT, reduced appetite

• Serious (rare): Interstitial lung disease, severe hepatic dysfunction—seek prompt medical attention for respiratory issues

• Other: Eye irritation, fatigue

❓ Frequently Asked Questions (FAQs)

Q. Who is Geftinat for?
A. Adults with EGFR–mutated advanced/metastatic NSCLC, as confirmed by molecular testing.

Q. How long is treatment continued?
A. Treatment is ongoing until disease progression or unacceptable toxicity, under oncologist supervision.

Q. Can it be taken with food?
A. No—take on an empty stomach to optimize absorption and effectiveness.

Q. What if a dose is missed?
A. If missed by less than 12 hours, take it once remembered. Otherwise, skip and take the next day at the regular time.